These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 19808353)

  • 1. Association between elevated fibrosis markers and heart failure in the elderly: the cardiovascular health study.
    Barasch E; Gottdiener JS; Aurigemma G; Kitzman DW; Han J; Kop WJ; Tracy RP
    Circ Heart Fail; 2009 Jul; 2(4):303-10. PubMed ID: 19808353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type 2 Diabetes Mellitus and Chronic Heart Failure with Midrange and Preserved Ejection Fraction: A Focus on Serum Biomarkers of Fibrosis.
    Lebedev DA; Lyasnikova EA; Vasilyeva EY; Babenko AY; Shlyakhto EV
    J Diabetes Res; 2020; 2020():6976153. PubMed ID: 33224989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between serum markers of collagen turnover and cardiovascular outcome in the elderly: the Cardiovascular Health Study.
    Barasch E; Gottdiener JS; Aurigemma G; Kitzman DW; Han J; Kop WJ; Tracy RP
    Circ Heart Fail; 2011 Nov; 4(6):733-9. PubMed ID: 21900186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy.
    Krum H; Elsik M; Schneider HG; Ptaszynska A; Black M; Carson PE; Komajda M; Massie BM; McKelvie RS; McMurray JJ; Zile MR; Anand IS
    Circ Heart Fail; 2011 Sep; 4(5):561-8. PubMed ID: 21750125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial.
    Pellicori P; Ferreira JP; Mariottoni B; Brunner-La Rocca HP; Ahmed FZ; Verdonschot J; Collier T; Cuthbert JJ; Petutschnigg J; Mujaj B; Girerd N; González A; Clark AL; Cosmi F; Staessen JA; Heymans S; Latini R; Rossignol P; Zannad F; Cleland JGF
    Eur J Heart Fail; 2020 Sep; 22(9):1711-1723. PubMed ID: 31950604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
    Lopez-Andrès N; Rossignol P; Iraqi W; Fay R; Nuée J; Ghio S; Cleland JG; Zannad F; Lacolley P
    Eur J Heart Fail; 2012 Jan; 14(1):74-81. PubMed ID: 22089058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
    Ravassa S; Trippel T; Bach D; Bachran D; González A; López B; Wachter R; Hasenfuss G; Delles C; Dominiczak AF; Pieske B; Díez J; Edelmann F
    Eur J Heart Fail; 2018 Sep; 20(9):1290-1299. PubMed ID: 29709099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction.
    Martos R; Baugh J; Ledwidge M; O'Loughlin C; Conlon C; Patle A; Donnelly SC; McDonald K
    Circulation; 2007 Feb; 115(7):888-95. PubMed ID: 17283265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive Value of Collagen Biomarkers for Heart Failure With and Without Preserved Ejection Fraction: MESA (Multi-Ethnic Study of Atherosclerosis).
    Duprez DA; Gross MD; Kizer JR; Ix JH; Hundley WG; Jacobs DR
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
    Cleland JGF; Ferreira JP; Mariottoni B; Pellicori P; Cuthbert J; Verdonschot JAJ; Petutschnigg J; Ahmed FZ; Cosmi F; Brunner La Rocca HP; Mamas MA; Clark AL; Edelmann F; Pieske B; Khan J; McDonald K; Rouet P; Staessen JA; Mujaj B; González A; Diez J; Hazebroek M; Heymans S; Latini R; Grojean S; Pizard A; Girerd N; Rossignol P; Collier TJ; Zannad F;
    Eur Heart J; 2021 Feb; 42(6):684-696. PubMed ID: 33215209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
    Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; O'Moore-Sullivan T; Marwick TH
    JACC Cardiovasc Imaging; 2011 Dec; 4(12):1239-49. PubMed ID: 22172779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis.
    Querejeta R; López B; González A; Sánchez E; Larman M; Martínez Ubago JL; Díez J
    Circulation; 2004 Sep; 110(10):1263-8. PubMed ID: 15313958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers of collagen type I metabolism are related to B-type natriuretic peptide, left ventricular size, and diastolic function in heart failure.
    Löfsjögård J; Kahan T; Díez J; López B; González A; Edner M; Henriksson P; Mejhert M; Persson H
    J Cardiovasc Med (Hagerstown); 2014 Jun; 15(6):463-9. PubMed ID: 24983265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-terminal B-type natriuretic peptide and the association with left ventricular diastolic function in a population at high risk of incident heart failure: results of the SCReening Evaluationof the Evolution of New-Heart Failure Study (SCREEN-HF).
    McGrady M; Reid CM; Shiel L; Wolfe R; Boffa U; Liew D; Campbell DJ; Prior D; Krum H
    Eur J Heart Fail; 2013 May; 15(5):573-80. PubMed ID: 23338855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of circulating markers of fibrosis and progression of left and right ventricular dysfunction in hypertensive patients with heart failure.
    Plaksej R; Kosmala W; Frantz S; Herrmann S; Niemann M; Störk S; Wachter R; Angermann CE; Ertl G; Bijnens B; Weidemann F
    J Hypertens; 2009 Dec; 27(12):2483-91. PubMed ID: 19887955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial).
    Trippel TD; Van Linthout S; Westermann D; Lindhorst R; Sandek A; Ernst S; Bobenko A; Kasner M; Spillmann F; González A; López B; Ravassa S; Pieske B; Paulus WJ; Díez J; Edelmann F; Tschöpe C
    Eur J Heart Fail; 2018 Mar; 20(3):460-470. PubMed ID: 28891228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic value of N-terminal B-type natriuretic peptide on all-cause mortality in heart failure patients with preserved ejection fraction].
    Cao J; Jin XJ; Zhou J; Chen ZY; Xu DL; Yang XC; Dong W; Li LW; Luo J; Chen L; Fu M; Zhou JM; Ge JB
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):875-881. PubMed ID: 31744276
    [No Abstract]   [Full Text] [Related]  

  • 18. Association between Markers of Fibrosis and Heart Failure Incidence in Patients with Type 2 Diabetes Mellitus.
    Lebedev DA; Lyasnikova EA; Vasilyeva EY; Likhonosov NP; Sitnikova MY; Babenko AY
    J Diabetes Res; 2021; 2021():9589185. PubMed ID: 34778465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating collagen metabolites, myocardial fibrosis and heart failure in aortic valve stenosis.
    Kupari M; Laine M; Turto H; Lommi J; Werkkala K
    J Heart Valve Dis; 2013 Mar; 22(2):166-76. PubMed ID: 23798204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study.
    Gaggin HK; Mohammed AA; Bhardwaj A; Rehman SU; Gregory SA; Weiner RB; Baggish AL; Moore SA; Semigran MJ; Januzzi JL
    J Card Fail; 2012 Aug; 18(8):626-34. PubMed ID: 22858078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.